Literature DB >> 20058865

Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors.

Janice Lawandi1, Sandrine Gerber-Lemaire, Lucienne Juillerat-Jeanneret, Nicolas Moitessier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20058865     DOI： 10.1021/jm901104g

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  21 in total

1.  Unveiling prolyl oligopeptidase ligand migration by comprehensive computational techniques.

Authors:  Martin Kotev; Daniel Lecina; Teresa Tarragó; Ernest Giralt; Víctor Guallar
Journal:  Biophys J       Date:  2015-01-06       Impact factor: 4.033

2.  Tetrazole as a Replacement of the Electrophilic Group in Characteristic Prolyl Oligopeptidase Inhibitors.

Authors:  Tommi P Kilpeläinen; Jonna K Tyni; Maija K Lahtela-Kakkonen; Tony S Eteläinen; Timo T Myöhänen; Erik A A Wallén
Journal:  ACS Med Chem Lett       Date:  2019-11-11       Impact factor: 4.345

3.  Increased angiotensin II-induced hypertension and inflammatory cytokines in mice lacking angiotensin-converting enzyme N domain activity.

Authors:  Frank S Ong; Chentao X Lin; Duncan J Campbell; Derick Okwan-Duodu; Xu Chen; Wendell-Lamar B Blackwell; Kandarp H Shah; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Kenneth E Bernstein
Journal:  Hypertension       Date:  2011-12-27       Impact factor: 10.190

4.  Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin.

Authors:  K N Lee; K W Jackson; V J Christiansen; E K Dolence; P A McKee
Journal:  J Thromb Haemost       Date:  2011-05       Impact factor: 5.824

5.  Potential Anticoagulant Activity of Trypsin Inhibitor Purified from an Isolated Marine Bacterium Oceanimonas Sp. BPMS22 and its Kinetics.

Authors:  B S Harish; Kiran Babu Uppuluri
Journal:  Mar Biotechnol (NY)       Date:  2018-08-18       Impact factor: 3.619

6.  Metabolic Instability of Cyanothiazolidine-Based Prolyl Oligopeptidase Inhibitors: a Structural Assignment Challenge and Potential Medicinal Chemistry Implications.

Authors:  Paolo Schiavini; Joshua Pottel; Nicolas Moitessier; Karine Auclair
Journal:  ChemMedChem       Date:  2015-05-28       Impact factor: 3.466

7.  Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent.

Authors:  Peter Serfozo; Jan Wysocki; Gvantca Gulua; Arndt Schulze; Minghao Ye; Pan Liu; Jing Jin; Michael Bader; Timo Myöhänen; J Arturo García-Horsman; Daniel Batlle
Journal:  Hypertension       Date:  2019-12-02       Impact factor: 10.190

8.  Structural analysis of prolyl oligopeptidases using molecular docking and dynamics: insights into conformational changes and ligand binding.

Authors:  Swati Kaushik; Ramanathan Sowdhamini
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

9.  Inhibition of Human Prolyl Oligopeptidase Activity by the Cyclotide Psysol 2 Isolated from Psychotria solitudinum.

Authors:  Roland Hellinger; Johannes Koehbach; Albert Puigpinós; Richard J Clark; Teresa Tarragó; Ernest Giralt; Christian W Gruber
Journal:  J Nat Prod       Date:  2015-04-20       Impact factor: 4.050

10.  Prolyl Oligopeptidase from the Blood Fluke Schistosoma mansoni: From Functional Analysis to Anti-schistosomal Inhibitors.

Authors:  Pavla Fajtová; Saša Štefanić; Martin Hradilek; Jan Dvořák; Jiří Vondrášek; Adéla Jílková; Lenka Ulrychová; James H McKerrow; Conor R Caffrey; Michael Mareš; Martin Horn
Journal:  PLoS Negl Trop Dis       Date:  2015-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.